The EFSUMB Guidelines and Recommendations for the Clinical Practice of Elastography in Non-Hepatic Applications : Update 2018

Funding Information: Odd Helge Gilja: Advisory Board/Consultant fee from: AbbVie, Bracco, GE Healthcare, Samsung, and Takeda Paul S. Sidhu: Speaker honoraria, Bracco, Siemens, Samsung, Hiatchi, GE and Philips Christoph F. Dietrich: Speaker honoraria, Bracco, Hitachi, GE, Mindray, Supersonic, Pentax, Olympus, Fuji, Boston Scientific, AbbVie, Falk Foundation, Novartis, Roche; Advisory, Board Member, Hitachi, Mindray, Siemens; Research grant, GE, Mindray, SuperSonic Vito Cantisani: Speaker honoraria, Canon/Toshiba, Bracco, Samsung Dominique Amy: Speaker honoraria, Hitachi, Supersonic, EpiSonica Marco Brock: Speaker honoraria, Hitachi Fabrizio Calliada: Speaker honoraria, Bracco, Hitachi, Shenshen Mindray Dirk Andre Clevert: Speaker honoraria, Siemens, Samsung, GE, Bracco, Philips; Advisory Board, Siemens, Samsung, Bracco, Philips Jean-Michel Correas: Speaker honoraria, Hitachi-Aloka, Canon/Toshiba, Philips, Supersonic, Bracco, Guerbet; Research collaboration, Bracco Sonocap, Guerbet NsSafe and Secure protocols Mirko D’Onofrio: Speaker honoraria, Siemens, Bracco, Hitachi; Advisory Board Siemens, Bracco Andre Farrokh: Speaker honoraria, Hitachi Pietro Fusaroli: Speaker honoraria, Olympus Roald Flesland Havre: Speaker honoraria, GE Healthcare, Conference participation support from Pharmacosmos, Ultrasound equipment from Samsung Medison André Ignee: Speaker honoraria: Siemens, Canon/Toshiba, Hitachi, Boston Scientific, Bracco, Supersonic, Abbvie Christian Jenssen: Speaker honoraria, Bracco, Hitachi, Canon/Toshiba, Falk Foundation, Covidien; Research grant, Novartis Maija Radzina: Speaker honoraria, Bracco, Canon/Toshiba Luca Sconfienza: Travel grants from Bracco Imaging Italia Srl, Esaote SPA, Abiogen SPA, Fidia Middle East. Speaker honoraria from Fidia Middle East Ioan Sporea: Speaker honoraria, Philips, GE, Canon/Toshiba; Advisory Board Member, Siemens; Congress participation support, Siemens Mickael Tanter: Speaker honoraria, Supersonic; Co Founder and shareholder, Supersonic; Research collaboration, Supersonic Peter Vilmann: Speaker honoraria, Pentax, Norgine; Advisory Board, Boston Scientific; Consultancy MediGlobe The following members declared no conflicts of interest: Adrian Săftoiu, Michael Bachmann Nielsen, Flaviu Bob, Jörg Bojunga, Caroline Ewertsen, Michael Hocke, Andrea Klauser, Christian Kollmann, Kumar V Ramnarine, Carolina Solomon, Daniela Fodor, Horia Ștefănescu Publisher Copyright: © 2019 Georg Thieme Verlag KG Stuttgart New York.This manuscript describes the use of ultrasound elastography, with the exception of liver applications, and represents an update of the 2013 EFSUMB (European Federation of Societies for Ultrasound in Medicine and Biology) Guidelines and Recommendations on the clinical use of elastography.Peer reviewe

A biomechanical analysis of shear wave elastography in pediatric heart models

Early detection of cardiac disease in children is essential to optimize treatment and follow-up, but also to reduce its associated mortality and morbidity. Various cardiac imaging modalities are available for the cardiologist, mainly providing information on tissue morphology and structure with high temporal and/or spatial resolution. However, none of these imaging methods is able to directly measure stresses or intrinsic mechanical properties of the heart, which are potential key diagnostic markers to distinguish between normal and abnormal physiology. This thesis investigates the potential of a relatively new ultrasound-based technique, called shear wave elastography (SWE), to non-invasively measure myocardial stiffness. The technique generates an internal perturbation inside the tissue of interest, and consequently measures the propagation of the acoustically excited shear wave, of which the propagation speed is directly related to tissue stiffness. This allows SWE to identify regions with higher stiffness, which is associated with pathology. SWE has shown to be successful in detecting tumors in breast tissue and fibrosis in liver tissue, however application of SWE to the heart is more challenging due to the complex mechanical and structural properties of the heart. This thesis provides insights into the acoustically excited shear wave physics in the myocardium by using computer simulations in combination with experiments. Furthermore, these models also allow to assess the performance of currently used SWE-based material characterization algorithms

Biomechanical Assessment and Monitoring of Thermal Ablation Using Harmonic Motion Imaging for Focused Ultrasound (HMIFU)

Cancer remains, one of the major public health problems in the United States as well as many other countries worldwide. According to the World Health Organization, cancer is currently the leading cause of death worldwide, accounting for 7.6 million deaths annually, and 25% of the annual death was due to Cancer during the year of 2011. In the long history of the cancer treatment field, many treatment options have been established up to date. Traditional procedures include surgical procedures as well as systemic therapies such as biologic therapy, chemotherapy, hormone therapy, and radiation therapy. Nevertheless, side-effects are often associated with such procedures due to the systemic delivery across the entire body. Recently technologies have been focused on localized therapy under minimally or noninvasive procedure with imaging-guidance, such as cryoablation, laser ablation, radio‐frequency (RF) ablation, and High Intensity F-ocused Ultrasound (HIFU). HIFU is a non-invasive procedure aims to coagulate tissue thermally at a localized focal zone created with noninvasively emitting a set of focused ultrasound beams while the surrounding healthy tissues remain relatively untreated. Harmonic Motion Imaging for Focused Ultrasound (HMIFU) is a dynamic, radiation-force-based imaging technique, which utilizes a single HIFU transducer by emitting an Amplitude-modulated (AM) beam to both thermally ablate the tumor while inducing a stable oscillatory tissue displacement at its focal zone. The oscillatory response is then estimated by a cross-correlation based motion tracking technique on the signal collected by a confocally-aligned diagnostic transducer. HMIFU addresses the most critical aspect and one of the major unmet needs of HIFU treatment, which is the ability to perform real-time monitoring and mapping of tissue property change during the HIFU treatment. In this dissertation, both the assessment and monitoring aspects of HMIFU have been investigated fundamentally and experimentally through development of both a 1-D and 2-D based system. The performance assessment of HMIFU technique in depicting the lesion size increase as well as the lesion-to-background displacement contrast was first demonstrated using a 3D, FE-based interdisciplinary simulation framework. Through the development of 1-D HMIFU system, a multi-parametric monitoring approach was presented where presented where the focal HMI displacement, phase shift (Δφ), and correlation coefficients were monitored along with thermocouple and PCD under the HIFU treatment sequence with boiling and slow denaturation. For HIFU treatments with slow denaturation, consistent displacement increase-then-decrease trend was observed, indicating tissue softening-then-stiffening and phase shift increased with treatment time in agreement with mechanical testing outcomes. The correlation coefficient remained high throughout the entire treatment time under a minimized broadband energy and boiling mechanism. Contrarily, both displacement and phase shift changes lacked consistency under HIFU treatment sequences with boiling due to the presence of strong boiling mechanism confirmed by both PCD and thermocouple monitoring. In order to facilitate its clinical translation, a fully-integrated, clinically 2D real-time HMIFU system was also developed, which is capable of providing 2D real-time streaming during HIFU treatment up to 15 Hz without interruption. Reproducibility studies of the system showed consistent displacement estimation on tissue-mimicking phantoms as well as monitoring of tissue-softening-then-stiffening phase change across 16 out of 19 liver specimens (Increasing rate in phase shift (Δφ): 0.73±0.69 %/s, Decreasing rate in phase shift (Δφ): 0.60±0.19 %/s) along with thermocouple monitoring (Increasing: 0.84±1.15 %/ °C, Decreasing: 2.03± 0.93%/ °C) and validation of tissue stiffening using mechanical testing. In addition, the 2-D HMIFU system feasibility on preclinical pancreatic tumor mice model was also demonstrated in vivo, where HMI displacement decreases were observed across three of five treatment locations on the kP(f)c model at 20.8±6.84, 18.6±1.46, and 24.0±5.43%, as well as across four of the seven treatment locations on the KPC model at 39.5±2.98%, 34.5±21.5%, 16.0±3.05%, and 35.0±3.12% along with H and E histological confirmation. In order to improve the quantitative monitoring aspect of HMIFU, a novel, model-independent method for the estimating Young's modulus based on strain profile was also implemented, where 1-D HMIFU system showed feasibilities on polyacrylamide phantom (EHMI/E ≈ 2.3) and liver specimen (EHMI/E ≈ 8.1), and 2-D HMIFU system showed feasibilities on copolymer phantom(EHMI/E ≈ 30.4), liver specimen(EHMI/E ≈ 211.3), as well as HIFU treated liver specimen (EHMI,end/EHMI,beginning ≈ 5.96). In conclusion, the outcomes from the aforementioned studies successfully showed the feasibility of both HMIFU systems in multi-parametric monitoring of HIFU treatment with slow denaturation and boiling, which prepares its stage towards clinical translation

Strain ultrasound elastography of aneurysm sac content after randomized endoleak embolization with sclerosing and non-sclerosing chitosan-based hydrogels in a preclinical model

Mise en contexte : La réparation endovasculaire des anévrismes de l’aorte abdominale est limitée par le développement des endofuites, qui nécessite un suivi à long terme par imagerie. L’élastographie sonore de déformation a été proposée comme méthode complémentaire pour aider à la détection des endofuites et la caractérisation des propriétés mécaniques des anévrismes. On s’intéresse ici également à la possibilité de suivre l’embolisation des endofuites, qui est indiquée dans certains cas mais dont le succès est variable. Un nouvel agent d’embolisation a été récemment créé en combinant un hydrogel de chitosane radio-opaque (CH) et le sclérosant tetradecyl sulfate de sodium (STS), qui s’appelle CH-STS. Le CH-STS démontre des propriétés mécaniques in vitro favorables, mais son comportement in vivo et son effet sur l’évolution du sac par rapport à un agent non-sclérosant pourraient être mieux caractérisés. L’objectif de cette étude était la caractérisation des propriétés mécaniques des composantes des endofuites embolisées avec CH-STS et CH avec élastographie sonore de déformation. Méthodologie : Des anévrismes bilatéraux avec endofuites de type I ont été créés au niveau des artères iliaques communes chez neuf chiens. Chez chaque sujet, une endofuite a été embolisée avec CH, et l’autre, avec CH-STS, d’une façon aléatoire et aveugle. Des images d’échographie duplex et des cinéloops pour élastographie sonore de déformation ont été acquis à 1 semaine, 1 mois, 3 mois et (chez 3 sujets) 6 mois post-embolisation. La tomodensitométrie a été faite à 3 mois et (si pertinente) 6 mois post-embolisation. L’histopathologie a été faite au sacrifice. Les études radiologiques et les données d’histopathologie ont été co-enregistrées pour définir trois régions d’intérêt sur les cinéloops : l’agent d’embolisation (au sacrifice), le thrombus intraluminal (au sacrifice) et le sac anévrismal (pendant chaque suivi). L’élastographie sonore de déformation a été faite avec les segmentations par deux observateurs indépendants. La déformation axiale maximale (DAM) a été le critère d’évaluation principal. Les analyses statistiques ont été faites avec des modèles mixtes linéaires généralisés et des coefficients de corrélations intraclasses (ICCs). Résultats : Des endofuites résiduelles ont été trouvées dans 7/9 (77.8%) et 4/9 (44.4%) des anévrismes embolisés avec CH et CH-STS, respectivement. Le CH-STS a eu une DAM 66 % plus basse (p < 0.001) que le CH. Le thrombus a eu une DAM 37% plus basse (p = 0.010) que le CH et 77% plus élevée (p = 0.079) que le CH-STS. Il n’y avait aucune différence entre les thrombi associés avec les deux traitements. Les sacs anévrismaux embolisés avec CH-STS ont eu une DAM 29% plus basse (p < 0.001) que ceux embolisés avec CH. Des endofuites résiduelles ont été associées avec une DAM du sac anévrismal 53% plus élevée (p < 0.001). Le ICC pour la DAM a été de 0.807 entre les deux segmentations. Conclusion : Le CH-STS confère des valeurs de déformations plus basses aux anévrismes embolisés. Les endofuites persistantes sont associées avec des déformations plus élevées du sac anévrismal.Background: Endovascular aneurysm repair (EVAR) is the modality of choice for the treatment of abdominal aortic aneurysms (AAAs). EVAR is limited by the development of endoleaks, which necessitate long-term imaging follow-up. Conventional follow-up modalities suffer from unique limitations. Strain ultrasound elastography (SUE) has been recently proposed as an imaging adjunct to detect endoleaks and to characterize aneurysm mechanical properties. Once detected, certain endoleaks may be treated with embolization; however, success is limited. In this context, the embolic agent CH-STS—containing a chitosan hydrogel and the sclerosant sodium tetradecyl sulphate (STS)—was created. CH-STS demonstrates favorable mechanical properties in vitro; however, its behavior in vivo and impact on sac evolution compared to a non-sclerosing chitosan-based embolic agent (CH) merit further characterization. Purpose: To compare the mechanical properties of the constituents of endoleaks embolized with CH and CH-STS—including the agent, the intraluminal thrombus (ILT), and the overall sac—via SUE. Methods: Bilateral common iliac artery aneurysms with type I endoleaks were created in nine dogs. In each animal, one endoleak was randomly embolized with CH, and the other with CH-STS. Duplex ultrasound (DUS) and radiofrequency cine loops were acquired at 1 week, 1 month, 3 months, and—in 3 subjects—6 months post-embolization. Contrast-enhanced CT was performed at 3 months and—where applicable—6 months post-embolization. Histopathological analysis was performed at time of sacrifice. Radiological studies and histopathological slides were co-registered to identify three regions of interest (ROIs) on the cine loops: embolic agent (at sacrifice), ILT (at sacrifice), and aneurysm sac (at all follow-up times). SUE was performed using segmentations from two independent observers on the cine loops. Maximum axial deformation (MAD) was the main outcome. Statistical analysis was performed using general linear mixed models and intraclass correlation coefficients (ICCs). Results: Residual endoleaks were identified in 7/9 (77.8%) and 4/9 (44.4%) aneurysms embolized with CH and CH-STS, respectively. CH-STS had a 66 % lower MAD (p < 0.001) than CH. The ILT had a 37% lower MAD (p = 0.010) than CH and a 77% greater MAD (p = 0.079; trending towards significance) than CH-STS. There was no difference in the ILT between treatment groups. Aneurysm sacs embolized with CH-STS had a 29% lower MAD (p < 0.001) than those with CH. Residual endoleak increased MAD of the aneurysm sac by 53% (p < 0.001), regardless of the agent used. The ICC for MAD was 0.807 between readers’ segmentations. Conclusion: CH-STS confers lower strain values to embolized aneurysms. Persistent endoleaks result are associated with increased sac strain, which may be useful for clinical follow-up